Sector News

Amgen R&D head Harper to leave for new pastures

July 30, 2018
Life sciences

Amgen’s head of R&D, Sean Harper, announced he is stepping down from the big biotech to pursue new opportunities in startups and early-stage companies.

Harper has led Amgen’s research work since taking over for Roger Perlmutter in 2012, inheriting a $3-billion-plus research budget, and helped guide the company to new product approvals in oncology, neuroscience, cardiovascular and kidney disease. He has spent the past 16 years at the company, joining as VP of development in 2002 from Merck Research Laboratories.

Amgen’s senior vice president of translational sciences and oncology, David Reese, will take over as executive VP of R&D, effective immediately, the company said in a statement. After joining Amgen in 2005, Reese has held roles in its development and medical sciences departments, and served as head of discovery research. Harper will stay on for a time to help with the transition.

In addition, the company’s executive VP of global commercial operations, Anthony Hooper, announced his retirement. Murdo Gordon, who recently left Bristol-Myers Squibb as commercial head, will take over in September.

“I would like to thank both Sean and Tony for the important contributions they have made to Amgen, each bringing their own vital experiences and skills,” said Amgen Chairman and CEO Robert Bradway. “They leave the company having established strong foundations within Research and Development and Global Commercial Operations for the future.”

Analysts at Jefferies said in a note to clients: “More exec changes in the industry. Neutral impact to Amgen for Street perspective.” The firm says that Harper “was fairly well-regarded in the biotech community given advancement of numerous drugs (PCSK9, CGRP, Bone health) and recently well known for his bullishness on bi-specifics instead of CAR-T.”

In May, Amgen and Novartis ushered in a new class of migraine drugs with the FDA’s approval of Aimovig, a calcitonin gene-related peptide receptor with blockbuster hopes. That landmark could prove important as the company begins to see new biosimilar competition for its tentpole products, such as Neulasta.

By Conor Hale

Source: Fierce Biotech

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach